These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 1708773

  • 21. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
    Clozel JP, Tschopp T, Luedin E, Holvoet P.
    Circulation; 1989 Jan; 79(1):125-33. PubMed ID: 2491972
    [Abstract] [Full Text] [Related]

  • 22. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits.
    Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirsh J.
    Blood; 1985 Aug; 66(2):399-401. PubMed ID: 4040410
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [Abstract] [Full Text] [Related]

  • 24. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster.
    Stassen JM, Nyström A, Hoylaerts M, Collen D.
    Circulation; 1995 Mar 01; 91(5):1330-5. PubMed ID: 7867170
    [Abstract] [Full Text] [Related]

  • 25. Synergism of thrombolytic agents in vivo.
    Collen D, Stassen JM, Stump DC, Verstraete M.
    Circulation; 1986 Oct 01; 74(4):838-42. PubMed ID: 3093116
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen.
    Refino CJ, Paoni NF, Keyt BA, Pater CS, Badillo JM, Wurm FM, Ogez J, Bennett WF.
    Thromb Haemost; 1993 Aug 02; 70(2):313-9. PubMed ID: 8236141
    [Abstract] [Full Text] [Related]

  • 31. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI.
    J Vasc Interv Radiol; 1995 Aug 02; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [Abstract] [Full Text] [Related]

  • 32. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM, Koster RW, Burggraaf J, Huisman LG, Kluft C, Kroon R, Schoemaker RC, Cohen AF.
    Clin Pharmacol Ther; 1998 Jan 02; 63(1):39-47. PubMed ID: 9465840
    [Abstract] [Full Text] [Related]

  • 33. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Holmes WE, Collen D.
    J Biol Chem; 1988 Apr 25; 263(12):5594-8. PubMed ID: 2965704
    [Abstract] [Full Text] [Related]

  • 34. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK, Schleuning WD.
    Thromb Haemost; 2004 Sep 25; 92(3):559-67. PubMed ID: 15351852
    [Abstract] [Full Text] [Related]

  • 35. [Development of new thrombolytic substances].
    Zeymer U, Neuhaus KL.
    Herz; 1994 Dec 25; 19(6):314-25. PubMed ID: 7843688
    [Abstract] [Full Text] [Related]

  • 36. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y, Umemura K, Takiguchi Y, Uematsu T, Nakashima M.
    Blood Coagul Fibrinolysis; 1993 Aug 25; 4(4):569-75. PubMed ID: 7692999
    [Abstract] [Full Text] [Related]

  • 37. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D, Dewerchin M, Rapold HJ, Lijnen HR, Stassen JM.
    Circulation; 1990 Nov 25; 82(5):1744-53. PubMed ID: 2121385
    [Abstract] [Full Text] [Related]

  • 38. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.
    Guerrero B, Arocha-Piñango CL, Pinto MA, Müller CA, Gil San Juan AG, Amorim S, Perales J.
    Blood Coagul Fibrinolysis; 2001 Oct 25; 12(7):521-9. PubMed ID: 11685039
    [Abstract] [Full Text] [Related]

  • 39. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D, Lijnen HR.
    Thromb Haemost; 1995 Jul 25; 74(1):167-71. PubMed ID: 8578451
    [Abstract] [Full Text] [Related]

  • 40. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P.
    Thromb Res; 2000 May 15; 98(4):333-42. PubMed ID: 10822080
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.